12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SEL-068: Phase I started

Selecta began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate 5 dose levels of subcutaneous SEL-068 in...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >